The panel committee reviewed non-clinical, clinical and post-marketing data of the drugs, and said that no updates to their prescribing information was required at the time. The agency has since April been monitoring the use of GLP-1 receptor agonists, a class of diabetes and weight loss drugs that includes Ozempic and Wegovy, for any signs that they increase the risk of thyroid cancer. The safety panel reviewed data from Novo's popular diabetes drug Ozempic and weight loss treatment Wegovy, which contain the same active ingredient, semaglutide.
Tip Sheet for ASHP Summer Meeting miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.